Table 2 Patient demographics and clinicopathologic characteristics in surgery cohort and Chinese validation cohort.
Demographic or characteristic | Total | Surgery cohort | Chinese cohort | P-value |
|---|---|---|---|---|
n = 1111 (100%) | n = 1018 (100%) | n = 93 (100%) | ||
Age | ||||
< 60 | 586 (52.7%) | 533 (52.4%) | 53 (57.0%) | 0.392 |
≥ 60 | 525 (47.3%) | 485 (47.6%) | 40 (43.0%) | |
Sex | ||||
Male | 14 (1.3%) | 14 (1.4%) | 0 (0.0%) | 0.255 |
Female | 1097 (98.7%) | 1004 (98.6%) | 93 (100%) | |
Year of diagnosis | ||||
2010–2012 | 538 (48.4%) | 498 (48.9%) | 40 (43.0%) | 0.275 |
2013–2015 | 573 (51.6%) | 520 (51.1%) | 53 (57.0%) | |
Socioeconomic status | ||||
High SES | 398 (35.8%) | 362 (35.6%) | 36 (38.7%) | 0.544 |
Low SES | 713 (64.2%) | 656 (64.4%) | 57 (61.3%) | |
Grade | ||||
Grade I | 48 (4.3%) | 45 (4.4%) | 3 (3.2%) | 0.586 |
Grade II | 473 (42.6%) | 429 (42.1%) | 44 (47.3%) | |
Grade III | 590 (53.1%) | 544 (53.4%) | 46 (49.5%) | |
Tumor size (mm) | ||||
< 20 | 108 (9.7%) | 94 (9.2%) | 14 (15.1%) | 0.187 |
20–50 | 585 (52.7%) | 540 (53.0%) | 45 (48.4%) | |
> 50 | 418(37.6%) | 384 (37.7%) | 34 (36.6%) | |
T stage | ||||
T1 | 108 (9.7%) | 96 (9.4%) | 12 (12.9%) | 0.732 |
T2 | 466 (41.9%) | 428 (42.0%) | 38 (40.9%) | |
T3 | 175 (15.8%) | 160 (15.7%) | 15 (16.1%) | |
T4 | 362 (32.6%) | 334 (32.8%) | 28 (30.1%) | |
N stage | ||||
N0 | 216 (19.4%) | 203 (19.9%) | 13 (14.0%) | 0.338 |
N1 | 570 (51.3%) | 521 (51.2%) | 49 (52.7%) | |
N2 | 133 (12.0%) | 123 (12.1%) | 10 (10.8%) | |
N3 | 192 (17.3%) | 171 (16.8%) | 21 (22.6%) | |
Chemotherapy | ||||
Yes | 433 (39.0%) | 395 (38.8%) | 38 (40.9%) | 0.697 |
No/unknown | 678 (61.0%) | 623 (61.2%) | 55 (59.1%) | |
Radiotherapy | ||||
Yes | 757 (68.1%) | 694 (68.2%) | 63 (67.7%) | 0.932 |
No/unknown | 354 (31.9%) | 324 (31.8%) | 30 (32.3%) | |
Metastasis pattern (yes vs. no) | ||||
Liver metastasis | 170 (15.3%) | 161 (15.8%) | 9 (9.7%) | 0.116 |
Brain metastasis | 19 (1.7%) | 17 (1.7%) | 2 (2.2%) | 0.732 |
Bone metastasis | 730 (65.7%) | 670 (65.8%) | 60 (64.5%) | 0.801 |
Lung metastasis | 261 (23.5%) | 237 (23.3%) | 24 (25.8%) | 0.582 |
Multiple sites | 194 (17.5%) | 174 (17.1%) | 20 (21.5%) | 0.283 |
Breast subtype | ||||
HR + /HER2- | 713 (64.2%) | 661 (64.9%) | 52 (55.9%) | 0.127 |
HR + /HER2 + | 160 (14.4%) | 142 (13.9%) | 18 (19.4%) | |
HR-/HER2 + | 91 (8.2%) | 79 (7.8%) | 12 (12.9%) | |
HR-/HER2- | 147 (13.2%) | 136 (13.4%) | 11 (11.8%) | |
Location | ||||
Central2 | 80 (7.2%) | 74 (7.3%) | 6 (6.5%) | 0.101 |
Upper | 372 (33.5%) | 340 (33.4%) | 32 (34.4%) | |
Lower | 125 (11.3%) | 115 (11.3%) | 10 (10.8%) | |
Axillary tail | 8 (0.7%) | 5 (0.5%) | 3 (3.2%) | |
Overlapping | 265 (23.9%) | 245 (24.1%) | 20 (21.5%) | |
Other3 | 261 (23.5%) | 239 (23.5%) | 22 (23.7%) | |
Marital status | ||||
Unmarried | 577 (51.9%) | 536 (52.7%) | 41 (44.1%) | 0.113 |
Married | 534 (48.1%) | 482 (47.3%) | 52 (55.9%) | |
